DiaMedica Therapeutics Announces Results of 2026 Annual General Meeting of Shareholders

On May 20, 2026, DiaMedica Therapeutics Inc. held its 2026 Annual General Meeting of Shareholders. During the meeting, shareholders voted on four key proposals. First, seven incumbent directors—Michael Giuffre, Rick Kuntz, Tanya Lewis, Daniel O’Connor, James Parsons, Rick Pauls, and Charles Semba—were re-elected to the Board of Directors to serve until the next annual meeting. Second, the appointment of Baker Tilly US, LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified. Third, shareholders approved the company's executive compensation on an advisory, non-binding basis. Finally, a proposal to amend and restate the Amended and Restated 2019 Omnibus Incentive Plan was approved, which includes an increase of 3,500,000 shares available for issuance under the plan. All proposals passed based on the final voting results disclosed in the filing.